Imperial College London

Dr. Elita Jauneikaite

Faculty of MedicineSchool of Public Health

Advanced Research Fellow







UG5Norfolk PlaceSt Mary's Campus





Dr Elita Jauneikaite's research focuses on evolution, transmission and antimicrobial resistance of vaccine preventable and healthcare associated bacterial infections. As her major research programme, Elita is investigating the disease-causing Group B Streptococcus (GBS), where she is using whole genome sequencing, bioinformatic analyses and molecular biology techniques to inform on evolution, mother-to-baby transmission and antimicrobial resistance patterns of this pathogen. Elita also leads genomics work investigating outbreaks and pathogenicity of other bacterial pathogens including E. coli, K. pneumoniae, methicillin-susceptible S. aureus, S. argenteus, S. pyogenes, S. pneumoniae and C. difficile

Elita is an Imperial College Research Fellow in Bacterial Genomics and Epidemiology at the Department of Infectious Disease Epidemiology and Research Lead for Priority Pathogens theme in the National Institute of Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance. The HPRU is a partnership between Imperial College London, Public Health England, Cambridge University, Warwick University and Imperial College Health Partners. The Unit was funded, along with 14 others in priority areas from immunisation to radiation hazards, to bring Universities to work in partnership with Public Health England to support excellent health protection research relevant to the needs of Public Health England. It commenced 01 April 2020 for a 5 year period and builds on the legacy of the previous HPRU which ran from 01 April 2014 -31 March 2020.

Elita completed her PhD in 2014 investigating the prevalence of serotypes and genotypes of disease-causing Streptococcus pneumoniae isolates in Singapore over the last 15 years. Elita used 1760 pneumococcal whole genome sequences to investigate the structure of this pneumococcal population in relation to the epidemiological data available and pneumococcal vaccine implementation in Singapore. This was achieved with a collaboration between four major hospitals in Singapore, Genome Institute of Singapore and University of Southampton.



Rodgus J, Prakapaite R, Mitsidis P, et al., 2022, Molecular epidemiology of Group B streptococci in Lithuania identifies multi-drug resistant clones and sporadic ST1 serotypes Ia and Ib, Pathogens, Vol:11, ISSN:2076-0817, Pages:1-11

Jauneikaite E, Honeyford K, Blandy O, et al., 2022, Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular-epidemiological study, Journal of Antimicrobial Chemotherapy, Vol:77, ISSN:0305-7453, Pages:1753-1761

Imai N, Gaythorpe K, Bhatia S, et al., 2022, COVID-19 in Japan, January – March 2020: insights from the first three months of the epidemic, Bmc Infectious Diseases, Vol:22, ISSN:1471-2334

Cordery R, Purba A, Begum L, et al., 2022, Frequency of transmission, asymptomatic shedding, and airborne spread of Streptococcus pyogenes in schoolchildren exposed to scarlet fever: a prospective, longitudinal, multicohort, molecular epidemiological, contact-tracing study in England, UK, The Lancet Microbe, Vol:3, ISSN:2666-5247, Pages:e366-e375

Taylor E, Jauneikaite E, Sriskandan S, et al., 2022, Novel 16S rRNA methyltransferase RmtE3 in acinetobacter baumannii ST79., Journal of Medical Microbiology, Vol:71, ISSN:0022-2615

More Publications